Sign In
Buy HSDT
$1.51
-0.120 (-7.36%)
At Close: Jun 23, 2026
Helius Medical Technologies, Inc. Announces Publication of its PoNS™ Registrational Clinical Trial (TBI-001) in TBI
11:05am, Thursday, 30'th Apr 2020
The TBI-001 trial found that PoNS Treatment™ provided significant improvement in balance in patients with a chronic balance deficit following a mild-to-moderate traumatic brain injury (“mmTBI”).
Hedge Fund Manager Makes Bold Tesla Prediction Ahead Of Earnings
12:00am, Wednesday, 29'th Apr 2020
Tesla Inc (NASDAQ: TSLA) traded higher by 2.5% on Wednesday ahead of the company’s first-quarter earnings report due out after the market close.
Glenn Tongue, general...
Helius Medical Technologies to Release First Quarter of Fiscal Year 2020 Financial Results on May 7, 2020
08:05pm, Wednesday, 22'nd Apr 2020
A live webcast of the call will also be provided on the Events section of the Company's investor relations website and can be accessed directly via the following link: https://78449.themediaframe.com/
Helius Medical Technologies Appoints Jeffrey S. Mathiesen to its Board of Directors
11:05am, Wednesday, 22'nd Apr 2020
Upon his appointment, Mr. Mathiesen will serve as Chair of the Company’s Audit Committee. “Jeff joins our Board of Directors with more than 25 years of experience as Chief Financial Officer of nu
Wave Life Sciences among public companies given small-business loan, AP reports WVE;LIND;QMCO;BWEN;MBII;HSDT;ENSV
10:21am, Tuesday, 21'st Apr 2020
Wave Life Sciences among public companies given small-business loan, AP reports WVE LIND QMCO BWEN MBII HSDT ENSV
Helius Medical Technologies (HSDT) Gets a Hold Rating from Oppenheimer
10:42pm, Thursday, 09'th Apr 2020
Oppenheimer analyst Steven Lichtman maintained a Hold rating on Helius Medical Technologies (HSDT) today. The company's shares closed last Thursday at
Helius Medical Technologies (HSDT) Gets a Hold Rating from Oppenheimer
10:42pm, Thursday, 09'th Apr 2020
Oppenheimer analyst
Steven Lichtman
maintained a
Hold
rating on Helius Medical Technologies (
HSDT
–
Research Report
) today. The company’s shares closed last Thursday at $0.26, close to its 52-we
The Daily Biotech Pulse: Genmark Pre-Announces Q1 Outperformance, Sage to Eliminate 53% of Workforce, Keros IPO
11:53am, Wednesday, 08'th Apr 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 7) * Dr.Reddy's Laboratories Ltd (NYSE: RDY) * Masimo C
Helius’ Portable Neuromodulation Stimulator (PoNS™) device is now authorized to be marketed for the short-term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from MS and is
The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection
12:00am, Thursday, 19'th Mar 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week highs on March 18)
Biomerica, Inc. (NASDAQ...
Helius Medical Technologies Announces $2.2 Million Registered Direct Offering
12:00pm, Wednesday, 18'th Mar 2020
Helius also agreed to issue to the investors unregistered warrants to purchase up to 6,257,144 shares of its common stock. The warrants have an exercise price of $0.46 per share of common stock, will
Can Helius Medical Technologies (NASDAQ:HSDT) Fund Its Growth Plans?
01:57pm, Sunday, 15'th Mar 2020
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
How one company is rewiring the brain
12:00am, Friday, 13'th Mar 2020
For thousands of Canadians suffering the effects of a mild or moderate brain injury — particularly issues with balance and gait — an innovative device and treatment program are providing benefits.
Helius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2019 Financial Results; Introduces Full Year 2020 Outlook
08:05pm, Thursday, 12'th Mar 2020
NEWTOWN, Pa., March 12, 2020 -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness,.
Helius Medical Technologies, Inc. Provides Details on Five Recently Authorized PoNS Treatment™ Clinics
11:05am, Monday, 09'th Mar 2020
Helius has now expanded access for patients seeking PoNS Treatment to fourteen clinics in Canada, with eight in Ontario, the most populous province. “Our progress in authorizing seven new clinics d
